1 Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation 2 clocks: a longitudinal study on senolytic interventions

3 Edwin Lee ^{#1}, Natàlia Carreras-Gallo ^{#2}, Leilani Lopez ², Logan Turner ², Aaron Lin², Tavis L.

4 Mendez², Hannah Went², Alan Tomusiak³, Eric Verdin³, Michael Corley⁴, Lishomwa Ndhlovu⁴,

- 5 Ryan Smith², Varun B. Dwaraka^{2*}
- 6 ¹ Institute For Hormonal Balance, Orlando, FL, United States
- 7 ² TruDiagnostic, Lexington, KY, United States
- 8 ³ Buck Institute for Research on Aging, Novato, CA, United States
- 9 ⁴ Cornell University, Ithaca, NY, United States
- 10 [#] These authors contributed equally
- 11 *Corresponding author: Varun B Dwaraka <u>varun@trudiagnostic.com</u>
- 12

13 Keywords

14 - Senolytics

- 15 Longitudinal Study
- 16 Epigenetic clocks
- 17 Aging
- 18 Immune system

19 Abstract

20 Senolytics, small molecules targeting cellular senescence, have emerged as potential 21 therapeutics to enhance health span. However, their impact on epigenetic age remains 22 unstudied. This study aimed to assess the effects of Dasatinib and Quercetin (DQ) senolytic 23 treatment on DNA methylation (DNAm), epigenetic age, and immune cell subsets. In a Phase I 24 pilot study, 19 participants received DQ for 6 months, with DNAm measured at baseline, 3 25 months, and 6 months. Significant increases in epigenetic age acceleration were observed in 26 first-generation epigenetic clocks and mitotic clocks at 3 and 6 months, along with a notable 27 decrease in telomere length. However, no significant differences were observed in second and 28 third-generation clocks. Building upon these findings, a subsequent investigation evaluated the 29 combination of DQ with Fisetin (DQF), a well-known antioxidant and antiaging senolytic 30 molecule. After one year, 19 participants (including 10 from the initial study) received DQF for 6 31 months, with DNAm assessed at baseline and 6 months. Remarkably, the addition of Fisetin to 32 the treatment resulted in non-significant increases in epigenetic age acceleration, suggesting a 33 potential mitigating effect of Fisetin on the impact of DQ on epigenetic aging. Furthermore, our 34 analyses unveiled notable differences in immune cell proportions between the DQ and DQF 35 treatment groups, providing a biological basis for the divergent patterns observed in the evolution of epigenetic clocks. These findings warrant further research to validate and 36 37 comprehensively understand the implications of these combined interventions.

38 Introduction

39 Senescence is defined as a stable growth arrest of cells that can limit the proliferation of 40 damaged cells, which is important for tissue homeostasis [1], [2]. However, senescent cells also 41 release harmful substances that can cause inflammation and damage to nearby healthy cells 42 [1], [3]. Recent studies suggest that senescence may contribute to aging and age-related 43 pathologies through the impossibility of tissue renewal by the stem cells caught in senescence 44 or through the chronic inflammation of nearby cells that can lead to tissue dysfunction [4]-[6]. In 45 fact, studies in mice have demonstrated that injecting senescent cells can induce age-related 46 conditions like osteoarthritis, frailty, and reduced lifespan [7], [8].

Aging is characterized by gradual functional decline [9]. It is associated with increased risk of
multiple chronic diseases, geriatric syndromes, impaired physical resilience, and mortality [9]–
[11]. For this reason, the pursuit of strategies to combat age-related diseases and promote
healthy aging has increased in recent years.

51 Given the potential role of senescence in aging, senolytic drugs have emerged as promising 52 candidates for extending lifespan. Some initially identified senolytics were Dasatinib, Quercetin, 53 and Fisetin [12]. These molecules were drugs or natural products already used for other 54 indications in humans, including anti-cancer therapies [13]-[15]. Dasatinib is a tyrosine kinase 55 inhibitor approved by the FDA to treat myeloid leukemia [12], [16]. Quercetin is a flavonoid 56 compound that induces apoptosis in senescent endothelial cells [12], [16]. Combined treatment 57 with Dasatinib and Quercetin (DQ) has been demonstrated to decrease senescent cell burden 58 in humans in multiple tissues [12], [17]-[20]; improve pulmonary and physical function along 59 with survival in mice while lessening their age-dependent intervertebral disc degeneration [7], 60 [21], [22]; and reduce senescence and inflammatory markers in non-human primates [23]. In 61 human studies, patients with idiopathic pulmonary fibrosis, a senescence associated disease, 62 improved 6-minute walk distance, walking speed, chair rise ability and short physical 63 performance battery after 9 doses of oral DQ over 3 weeks [24]. Fisetin is another flavonoid 64 compound that has gained recognition for its anti-proliferative, anti-inflammatory, and anti-65 metastatic properties [15], [25]. Fisetin has the potential to reduce senescence markers in multiple tissues in murine and human subjects [12], [26]. Administration of Fisetin to old mice 66 67 restored tissue homeostasis, reduced age-related pathology, and extended median and 68 maximum lifespan [26]. Notably, a comparative study has highlighted Fisetin as the safest and 69 most potent natural senolytic among the tested compounds [26].

To date, research has not determined the effect of senolytics in biological aging measured by molecular biomarkers, such as the length of the telomeres, the proportion of immune cells, and the alteration of DNA Methylation. DNA methylation (DNAm) has emerged as a widely used biomarker for predicting health span and age-related diseases [27], [28]. The widely used firstgeneration clocks, such as the Hannum clock and Horvath clocks, analyze DNAm patterns to estimate an individual's chronological age [29], [30]. Second-generation clocks, including the DNAmPhenoAge and GrimAge, instead of being trained to predict chronological age, have been trained to predict biological phenotypes, which has increased the hazard ratio prediction of agerelated outcomes [31], [32]. Moreover, a third-generation clock, the DunedinPACE, measures
the rate of aging rather than providing an overall age estimation [33].

Therefore, this study aims to comprehensively assess the impact of senolytic drugs on epigenetic aging through two longitudinal studies to address our research objective. The initial investigation focuses on a combination treatment of Dasatinib and Quercetin, while the subsequent phase incorporates Fisetin into the treatment regimen, allowing for the evaluation of aging effects over a two-year period. This comprehensive approach will provide insights into how senolytic drugs influence epigenetic dynamics and contribute to our understanding of potential interventions in the process of senescence.

87

88 <u>Results</u>

89 Figure 1 shows the design of the study. 28 individuals were enrolled in our cohort and split 90 across two different studies. In the first study, a total of 19 participants underwent a 6-month 91 treatment period with DQ, and blood samples were taken at baseline, 3 months, and 6 months. 92 The age range of these individuals was between 43.0 and 86.6 (Table 1). Following the 93 completion of the initial treatment period, participants remained untreated for a duration of one 94 year. Out of the initial group, 10 participants continued in the trial, while 9 new participants 95 joined the study. In the second trial, all participants underwent a 6-month treatment with DQ and 96 Fisetin, with measurements taken at baseline and 6 months. The average age of the 97 participants in these two studies was 60.9, ranging from 44.5 to 88.0. The percentage of male 98 participants varied across the studies: 57.9% in the DQ study and 42.1% in the DQF study. 99

100 **Table 1. Characteristics of participants in both trials.**

	Dasatinib and Quercetin study	Dasatinib, Quercetin, and Fisetin study		
Sample Size	19	19		
Age in years, mean (range)	59.6 (43.0 - 86.6)	60.9 (44.5 - 88.0)		
Sex, male	11 (57.9%)	8 (42.1%)		



102

Figure 1. Timeline diagram for the study design. In the first study, 19 individuals were treated with 50mg of Dasatinib and 500mg of Quercetin. After one year, the second study started with 10 participants from the first study and 9 new participants. These individuals were treated with 50mg of Dasatinib, 500mg of Quercetin, and 500mg of Fisetin.

107

108

109

110 Impact of senolytic drugs on epigenetic age

To investigate the impact of the combination of DQ and the combination of DQF on epigenetic age, we assessed biological age using the principal component versions of multiple epigenetic clocks: the first-generation Horvath pan tissue clock, the Horvath skin and blood clock, and the Hannum clock; the second generation DNAmPhenoAge and GrimAge; and third generation DunedinPACE. For these clocks except DunedinPACE, we calculated the epigenetic age acceleration (EAA) after adjusting the values by age and principal components.

117 We observed that PC Horvath pan tissue EAA significantly increased after 3 months of DQ 118 treatment (p-value= $6.7 \cdot 10^{-06}$). However, this increase was followed by a decrease 3 months 119 later (p-value= $2.6 \cdot 10^{-4}$), resulting in non-significant differences between the baseline and the 6-120 month time point (p-value=0.23) (**Figure 2A**; **Table 2**). Besides, we detected a significant 121 increase in this clock after 6 months of DQF treatment (p-value=0.017, see **Table 3**).



122

Figure 2. Boxplot showing the evolution of epigenetic age acceleration (EAA) first-generation clocks in the Dasatinib and Quercetin (DQ) study. (A) PC Horvath pan tissue EAA. (B) PC Horvath Skin&Blood EAA. (C) PC Hannum EAA. In the X-axis, the time points of measurements, in the Y axis, the EAA measure. On the top, the mean values at each time points. The p-values of the paired t-tests are

127 also displayed in the plots.

128

129 Regarding the other first-generation clocks, PC Horvath Skin&Blood EAA and PC Hannum EAA,

130 we identified a significant increase following DQ treatment, particularly at the 3-month period

131 (Figure 2B-C; Table 2). However, we did not observe significant changes in EAA after DQF

132 treatment for these clocks (**Table 3**).

For second-generation clocks, we observed a significant increase between baseline and 3month test after DQ treatment in PC DNAmPhenoAge (p-value=0.005) and between baseline and 6-month test (p-value=0.038). On the other hand, PC GrimAge and the third-generation clock, DunedinPACE, remained stable after the treatment. For DQF treatment, all the second and third-generation clocks were unchanged.

138 We also evaluated the changes observed by the recently developed IntrinClock, as it is agnostic

to immune cell changes that have been shown to influence the reliable quantification of

140 epigenetic age [34]. However, no significant differences were observed in any of the trials.

141 Table 2. Statistical analysis for comparing baseline, 3 months, and 6 months epigenetic age 142 acceleration (EAA) in the Dasatinib and Quercetin Study. The first three columns show the mean 143 values for each EAA clock at each time point. The next columns have information about the t-test 144 between baseline and 3-month test, between baseline and 6-month test, and between 3-month and 6-145 month tests, respectively.

146

	Mean			Baseliı mo	Baseline vs 3- month		Baseline vs 6- month		3-month vs 6- month	
	Base	3m	6m	T-score	P-value	T-score	P-value	T-score	P-value	
PC Horvath pan tissue EAA	-1.485	1.254	-0.926	-6.258	6.7·10 ⁻⁶	-1.230	0.234	4.527	2.6·10 ⁻⁴	
PC Horvath Skin and Blood	-0.625	0.194	-0.064	-2.450	0.025	-1.075	0.297	0.598	0.557	
EAA PC Hannum EAA	-1.165	0.474	0.184	-3.622	0.002	-2.561	0.020	0.546	0.592	
PC GrimAge EAA	-0.173	-0.179	0.374	0.016	0.988	-1.431	0.170	-1.476	0.157	
PC DNAmPheno Age EAA	-1.766	0.891	0.134	-3.237	0.005	-2.240	0.038	0.936	0.362	
PC DNAmTL EAA	0.043	-0.024	-0.010	5.098	7.5·10 ⁻⁵	4.286	4.4·10 ⁻⁴	-0.931	0.364	
DunedinPACE	0.929	0.923	0.927	0.392	0.699	0.112	0.912	-0.230	0.821	
Intrinclock EAA	0.039	-0.428	0.389	0.714	0.484	-0.499	0.624	-1.235	0.233	

147

148Table 3. Statistical analysis for comparing baseline and 6-month epigenetic age acceleration149(EAA) in the Dasatinib, Quercetin, and Fisetin Study. The first two columns show the mean values for150each EAA clock at each time point. The next columns have information about the t-test between baseline151and 6-month test.

	Me	an	Baseline v	s 6-month
	Baseline	6-month	T-score	P-value
PC Horvath pan tissue EAA	-0.201	1.607	-2.643	0.017
PC Horvath Skin and Blood EAA	-0.057	0.826	-1.838	0.083
PC Hannum EAA	-0.162	0.853	-1.774	0.093
PC GrimAge EAA	0.101	0.057	0.140	0.890
PC DNAmPhenoAge EAA	-0.033	0.964	-1.094	0.288
PC DNAmTL EAA	0.005	-0.027	1.698	0.107
DunedinPACE	0.937	0.918	1.016	0.323
Intrinclock EAA	0.637	-0.637	1.608	0.125

154 Impact of senolytic drugs on DNAm Telomere length and Mitotic Clock Epigenetic 155 Methylation Prediction Algorithms

156 Cells with critically short telomere lengths are also known to undergo senescence once they 157 approach their Hayflick limit [35], therefore we investigated the potential changes due to 158 telomere length using the DNAm predictor for telomere length (DNAmTL) [36]. We found significant alterations in the DQ group, but not in the DQF group. Specifically, we observed a 159 160 significant decrease in PC DNAm telomere length after the whole treatment (p-value=0.01, see **Figure 3A**), which was even more significant after adjusting by age (p-value= $4.4 \cdot 10^{-4}$, see 161 Figure 3B). Importantly, the difference in telomere length acceleration between baseline and 3 162 months was larger and more significant (p-value= $7.5 \cdot 10^{-5}$) than the difference between baseline 163 and 6 months (p-value= $4.4 \cdot 10^{-4}$). 164







Figure 3. Boxplot showing the evolution of DNA methylation (DNAm) based telomere length in the DQ study. (A) DNAm telomere length. (B) DNAm telomere length acceleration. In the X-axis, the time points of measurements, in the Y axis, the epigenetic metric. On the top, the mean values at each time point. The p-values of the paired t-tests are also displayed in the plots.

171

172 Mitotic clock metrics were also employed to evaluate relative changes in stem cell replication. At 173 the 3-month mark of DQ treatment, we observed a decrease in both the total number of stem 174 cell divisions and the intrinsic tissue stem cell divisions, although these changes were not 175 statistically significant (p-value=0.22 and p-value=0.22, respectively, see **Figure 4**). However, 176 between 3-month and 6-month points, a significant increase was evident in both mitotic clocks 177 (p-value= $2.4 \cdot 10^{-4}$ and p-value= $7.8 \cdot 10^{-4}$, respectively). In the case of DQF treatment, no 178 significant differences were found between the baseline and the 6-month measurement.

179





Figure 4. Boxplot showing the evolution of mitotic clocks in the Dasatinib and Quercetin study. (A) Total number of stem cell divisions. (B) Intrinsic tissue stem cell division. In the X-axis, the time points of measurements, in the Y axis, the number of divisions. On the top, the mean values at each time point. The p-values of the paired t-tests are also displayed in the plots.

185

186 Impact of senolytic drugs on whole blood immune cell composition

187 We utilized EpiDISH (2023) to quantify 12 different immune cell subsets and assess changes 188 within these subsets. During the 6-month period of DQ treatment, significant alterations were 189 observed in CD4T Naive cells, B Naive cells, and monocytes (Table 4). The most notable and 190 significant change was in CD4T Naive Cells, which exhibited a slight decrease at the 3-month 191 mark (p-value=0.628) and experienced a more substantial decline between the 3 and the 6-192 month marks (p-value=0.029). B Naive cells displayed an insignificant increase for the global 193 treatment (p-value=0.059), but we observed a significant increase between 3 and 6 months (p-194 value=0.001). Monocytes showed a global increase after 6 months of treatment (p-value=0.003) that was characterized by a significant decrease at 3 months (p-value=0.035) followed by a 195 significant increase between 3 and 6 months (p-value=3.0·10⁻⁵). Conversely, CD4T Memory, 196 197 CD8T Naive, CD8T Memory, B Memory, basophil, regulatory T cells, eosinophil, Natural Killer, 198 and Neutrophil did not exhibit significant changes.

199 Table 4. Statistical analysis for comparing baseline, 3 months, and 6 months immune cell 200 proportions in the Dasatinib and Quercetin Study. The first three columns show the mean values for 201 each immune cell proportion at each time point. The next columns have information about the t-test 202 between baseline and 3-month test, between baseline and 6-month test, and between 3-month and 6-203 month tests, respectively.

204

	Mean			Basel 3-m	Baseline vs 3-month		Baseline vs 6-month		3-month vs 6-month	
	Base	3m	6m	T-score	P-value	T-score	P-value	T-score	P-value	
CD4T naive cells	0.077	0.074	0.060	0.493	0.628	2.228	0.039	2.364	0.029	
Basophiles	0.020	0.021	0.020	-1.147	0.266	-0.408	0.688	0.439	0.666	
CD4T memory cells	0.084	0.081	0.079	0.535	0.599	0.639	0.531	0.410	0.686	
B memory cells	0.019	0.017	0.019	1.287	0.214	-0.457	0.653	-1.380	0.184	
B naive cells	0.040	0.035	0.046	1.611	0.125	-2.018	0.059	-3.907	0.001	
T regulatory cells	0.005	0.007	0.008	-0.978	0.341	-1.946	0.067	-0.842	0.411	
CD8T memory cells	0.051	0.052	0.049	-0.290	0.775	0.359	0.724	0.650	0.524	
CD8T naive cells	0.025	0.028	0.026	-1.354	0.193	-0.456	0.654	0.607	0.552	
Eosinophiles	0.009	0.009	0.005	0.306	0.763	1.400	0.178	1.036	0.314	
Natural Killer	0.044	0.047	0.048	-0.696	0.495	-1.046	0.309	-0.339	0.739	
Neutrophiles	0.564	0.575	0.556	-0.612	0.548	0.309	0.761	0.966	0.347	
Monocytes	0.062	0.053	0.082	2.282	0.035	-3.415	0.003	-5.527	3.0·10 ⁻⁵	

205

206

Regarding the impact of DQF on immune cells, B Naive cells (Bnv) demonstrated a significant decrease after 6 months (p-value= $3.0 \cdot 10^{-4}$), which contrasts with the observations from DQ treatment. No significant changes were observed in the proportions of other immune cell subsets (**Table 5**).

211

212

213

214

Table 5. Statistical analysis for comparing baseline and 6-month immune cell proportions in the Dasatinib, Quercetin, and Fisetin Study. The first two columns show the mean values for each immune cell proportion at each time point. The next columns have information about the t-test between baseline and 6-month test.

220

	Ме	an	Baseline	vs 6-month	
	Baseline	6-month	T-score	P-value	
CD4T naive cells	0.065	0.063	0.200	0.844	
Basophiles	0.014	0.013	0.507	0.618	
CD4T memory cells	0.081	0.089	-0.926	0.367	
B memory cells	0.017	0.015	1.122	0.277	
B naive cells	0.040	0.024	4.470	3.0·10 ⁻⁴	
T regulatory cells	0.006	0.004	2.069	0.053	
CD8T memory cells	0.063	0.058	0.950	0.354	
CD8T naive cells	0.020	0.017	1.202	0.245	
Eosinophiles	0.011	0.011	-0.009	0.993	
Natural Killer	0.055	0.048	1.620	0.123	
Neutrophiles	0.569	0.597	-1.336	0.198	
Monocytes	0.060	0.062	-0.421	0.679	

221

222

223 Since most of the epigenetic clocks, especially the first-generation clocks, are dependent on 224 immune subsets, we calculated the correlation between the EAA metrics and the immune cells 225 proportions. As expected, we did not observe significant correlations between IntrinClock and 226 immune cells. However, we observed high correlations between the other clocks and most of 227 the immune cells (Figure 5). Thus, we decided to calculate immune EAA adjusting EAA values 228 by all the immune cells that were significantly associated to the clocks (CD4T naive and 229 memory cells, B naive and memory cells, CD8T naive and memory cells, natural killers, and 230 neutrophils) and see whether the trends in first-generation clocks after DQ treatment were 231 maintained. We found that the significance and direction of the associations were not modified 232 after adjusting by immune cells, indicating that the increase of epigenetic age after DQ 233 treatment was not due to the alteration of immune cell subsets (Supplementary Figure S1).



234

Figure 5. Correlation between epigenetic clocks and immune cell types. The size of the dots is proportional to the correlation value, being blue a positive correlation and red a negative correlation.

237

238 Impact of senolytic drugs on whole-genome DNA methylation

We also assessed global modification of DNAm in those individuals who were treated with DQ and those with DQF. To this end, we performed an Epigenome-wide association study (EWAS) comparing the methylation levels for all the CpG sites in the genome at different timepoints in each trial (**Supplementary Table S1**).

The first EWAS was performed between baseline and 3 months of DQ treatment. In this case, we identified 11 CpG sites differentially methylated, 4 of them hypermethylated and 7 hypomethylated after 3 months. These probes were mapped to 8 genes. Among them, *TGIF1*, *SORBS2*, and *ZNF768* were implicated in senescence [37]–[39]. Using a less restrictive threshold of p-value lower than $1 \cdot 10^{-4}$, we performed an enrichment analysis. Among the 305 probes identified, we found three enriched processes highly related with senescence, such as glycolic process, vesicle recycling and endocytosis, and cytoskeletal organization [40]–[42].

250 Second, we evaluated the differences at global methylation between baseline and 6 months 251 after DQ treatment. In this case, we only saw 2 CpG sites differentially methylated with an adjusted p-value lower than 0.05. One of them was hypermethylated and the other hypomethylated after a period of 6 months. The GREAT analysis was performed with the 475 CpG sites with a nominal p-value lower than $1 \cdot 10^{-4}$. Although multiple gene ontology terms were identified as enriched, none of them were directly associated with aging or senescence.

Finally, when we compared the methylation levels between baseline and 6 months after DQF treatment, we identified 208 significant probes. Among them, approximately 50% were hypomethylated and 50% were hypermethylated. The GREAT analysis was performed using 556 probes and revealed multiple enriched pathways associated with senescence, such as epithelial cell proliferation, platelet dense granule membrane, cell junction, and positive regulation of cardiac muscle cell apoptotic process [43]–[47].

262

263 Clinical and DNAm Proteomic Surrogate Analysis

The major hypothesized mechanism for the negative impacts of senescence is through the increased senescence-associated secretory phenotypes (SASP) which lead to high inflammatory cytokine signaling from senescent cells in a paracrine fashion. As an alternative to robust clinical lab measurements of inflammatory mediators, we used methylation risk scores surrogates to predict and quantify predicted changes in circulating proteomic markers [48]. The quantification of these markers and the comparison between the different timepoints are included in **Supplementary Table S2**).

We paid special attention to inflammation and inflammatory proteomic EpiScore analysis and these are listed in **Table 6**. In this analysis, we see some increased inflammatory mediators at 3 months which decrease from the 3 to 6-month timepoints. These inflammatory associated proteins include CRP, CXCL9, CXCL11, CCL17, and TGF-alpha. We see opposite trends with other inflammation associated markers such as Complement C4 and Complement C5a. Many inflammatory mediators for the innate adaptive immune system were not registered as significant in this analysis.

- 278
- 279 280 281 282 283 284 285 286
- 287

Table 6. Inflammation and inflammatory proteomic EpiScore analysis between baseline, 3-month test, and 6-month test in the Dasatinib and Quercetin (DQ) trial. The first three columns show the mean values for each protein methylation risk score (MRS) at each time point. The next columns have information about the t-test between baseline and 3-month test, between baseline and 6-month test, and between 3-month and 6-month tests, respectively.

293

	Mean			Baseliı mo	Baseline vs 3- month		Baseline vs 6- month		3-month vs 6- month	
	Base	3m	6m	T-score	P-value	T-score	P-value	T-score	P-value	
CCL11	-0.007	-0.007	-0.004	0.071	0.944	-2.94	0.009	-3.97	0.001	
CCL17	-0.434	-0.428	-0.435	-3.306	0.004	1.062	0.302	3.614	0.002	
CCL18	-0.15	-0.15	-0.148	0.002	0.998	-1.443	0.166	-1.722	0.102	
CCL21	-0.127	-0.128	-0.127	1.449	0.165	0.06	0.953	-1.473	0.158	
CCL22	-0.066	-0.065	-0.064	-0.428	0.674	-3.241	0.005	-3.269	0.004	
Complement C4	0.032	0.031	0.033	2.923	0.009	-1.723	0.102	-4.513	2.7·10 ⁻⁴	
Complement C5a	0.155	0.148	0.158	3.721	0.002	-2.268	0.036	-6.877	2.0·10 ⁻⁵	
Complement C9	-0.013	-0.012	-0.011	-0.545	0.592	-0.751	0.462	-0.229	0.822	
CRP	-0.114	-0.107	-0.115	-4.888	1.2·10 ⁻⁴	0.979	0.34	4.679	1.9·10 ⁻⁴	
CXCL10 soma	-0.345	-0.338	-0.343	-2.939	0.009	-0.966	0.347	1.911	0.072	
CXCL11 soma	-0.053	-0.05	-0.054	-3.291	0.004	1.282	0.216	5.23	5.7·10 ⁻⁵	
CXCL9	-0.034	-0.031	-0.037	-3.347	0.004	2.728	0.014	5.132	7.0·10 ⁻⁵	
Interleukin 19	-0.002	-0.005	-0.005	1.064	0.302	1.241	0.231	0.188	0.853	
TGF alpha	0.021	0.026	0.018	-2.842	0.011	1.29	0.213	3.989	0.001	
TNFRSF1B	-0.106	-0.104	-0.105	-1.898	0.074	-1.028	0.317	0.525	0.606	
Relative IL6 Level	-0.079	-0.086	-0.041	0.501	0.622	-2.495	0.023	-3.292	0.004	

294

295

297 Discussion

Overall, our findings indicate that the administration of senolytic drugs Dasatinib and Quercitin significantly increases biological age measured by first generation clocks. The only 2nd generation clock to show an increase was DNAmPhenoAge. However, we see no significant change in second and third-generation clocks such as GrimAge and DunedinPACE or any significant changes with the addition of Fisetin to the protocol (DQF treatment).

The increase in DNAmPhenoAge is different in trend from the other phenotypically trained clocks but is not surprising as this clock has previously been described as a hybrid between first and second-generation clocks. Unlike GrimAge and DunedinPoAm, the dependent variable used for training DNAmPhenoAge, also included chronological age. While GrimAge included observed age in its derivation on the other side of the equation—as a predictor along with DNAm—essentially adjusting out its effects. This similarity is further described by its module composition which reflects similarity to first generation trained chronological clocks [49].

The biological aging impacts effects of this analysis are difficult to analyze. While, the link between cellular senescence and aging is indisputable [50]. The differential analysis of these clocks limits our interpretation of their clinical significance.

Previous studies have shown that the first-generation clocks, such as the Skin&blood clock, will increase with cell passage and time in cell culture. This increase was shown irrespective of cells which have human telomerase reverse transcriptase (hTERT) expressed and thus didn't enter replicative senescence or have telomere attrition which suggest that these first-generation clocks are measuring a process separate from either senescence or telomere attrition [51]. This suggests that epigenetic age clocks might not do a good job in measuring the process of senescence or the biological impact of senescence.

320 However, the non-significant change in 2nd and 3rd generation clocks such as GrimAge and 321 DunedinPACE is also informative. 2nd and 3rd generation clocks, trained to phenotypes of 322 aging, are more prone to capture the underlying biology of aging since these are trained to 323 biomarkers of the biological aging process and not just correlating CpGs to chronological age. It 324 is plausible that the significant biological age increases that are seen in the first-generation 325 clocks, and DNAmPhenoAge, might be accelerated due to the age correlated CpG locations and not the underlying biological relevant impacts since the more predictive, and more biological 326 associated, 2nd and 3rd generation clocks are not showing the same increase. Thus, while 327 328 neither generation of clocks are showing improvement with senolytic treatment, the increases in 329 the 1st generation clocks are less reliable for predicting the phenotypic outcomes and thus 330 should be interpreted carefully.

This ability for different generations of clocks to reflect different interventional change is not new. In previous DNAm interventional studies such as the CALERIE study, we see that caloric restriction only displayed significant aging changes with DunedinPACE, yet didn't show significance with any other clock [52]. 335 Another confounding variable which limits our ability to establish biological aging significance is 336 the significant changes in CD4T and CD8T Naive cells, B Naive cells, and monocytes. Immune 337 cell changes with aging have been a large confounding error in previous DNAm clocks. For 338 instance, previous studies have shown that human naive CD8+ T cells can exhibit an epigenetic 339 age 15–20 years younger than effector memory CD8+ T cells from the same individual. This 340 means that previous epigenetic clocks measure two independent variables, aging and immune 341 cell composition [53]. To analyze if immune changes were responsible for the first-generation 342 epigenetic clock acceleration, we calculated immune EAA and adjusted by all the immune cells 343 that were significantly associated to the clocks (CD4T naive and memory cells, B naive and 344 memory cells, CD8T naive and memory cells, natural killers, and neutrophils). We found that the 345 significance and direction of the associations were not modified after adjusting by immune cells, 346 indicating that the increase of epigenetic age after DQ treatment was not due to the modulation 347 of immune cell subsets but representing an increase due to the CpG inclusion and weights of 348 the clocks themselves.

349 Furthermore, we also analyzed the IntrinClock to assess the relationship of immune cell 350 subtypes. The IntrinClock was created to be independent of immune cell subset changes. And 351 created through an analysis of the age-related changes in independent cell types. This clock 352 showed no significant change in any of the treatment arms. This might be due to the unique 353 construction method for the IntrinClock. IntrinClock was generated via the deliberate removal of 354 CpGs that were characteristic of naïve cells. It is possible that senolytic treatment is affecting a 355 subset of CpGs that were removed in the construction of the IntrinClock that are more 356 correlated to general properties of naïve cells (guiescence, etc.) rather than those that represent 357 immune cell type composition specifically.

358 The major hypothesized mechanism for the negative impacts of senescence is through the 359 increased senescence-associated secretory phenotypes (SASP) which lead to high 360 inflammatory cytokine signaling from senescent cells in a paracrine fashion. Although SASP 361 proteins were not measured directly in this study, we used DNA methylation risk scores for 362 protein surrogates to analyze changes in common SASP proteins. In some cases, these 363 methylation risk scores have been shown to have better resolution and connection to outcomes 364 than traditional measures. For instance, the Episcore for C-Reactive protein has shown age-365 related associations in cohorts which were not seen with log(CRP) clinical measures and 366 association to cognitive function and brain MRIs [54]. Looking at these methylation risk scores in 367 our longitudinal data, we see some interesting trends of increased inflammatory mediators at 3 368 months which decrease from the 3-6 month timepoints. These inflammatory associated proteins 369 include CRP, CXCL9, CXCL11, CCL17, and TGF-alpha. We see opposite trends with other 370 inflammation associated markers such as Complement C4 and Complement C5a. The accuracy 371 of the EpiScore protein predictions to measured proteins is still low. Thus, the changes we see 372 here are limited by accuracy of the prediction. CRP, which is the most validated of the 373 proteomic EpiSign scores, shows decreases at 3 months and increases at 6 months which 374 might suggest duration of senolytic therapy might impact the phenotypic outcomes. 375 Furthermore, the treatment impacts on the SASP might also indicate a plausible explanation for the differences in age accelerations between the first generation IntrinClock and other firstgeneration clocks. SASP-related CpG sites would be differentially methylated in naïve T cells
and thus removed from construction of the IntrinClock but not Horvath, Hannum, or PhenoAge.
Clocks.

Together, our findings suggest that 1st generation clocks are insufficient tools to quantify the impact of senolytic therapies. Additionally, second generation clocks still remain largely unchanged with Dasatinib and Quercetin use and other markers are needed to measure the physiologic impact of senolytic treatments. In either instance, our findings reemphasize the importance of developing new biomarkers which can quantify senescence and impact to aging phenotypes.

386 Strengths of the present study include its prospective longitudinal design, the duration of 387 longitudinal measures, the standardized and batch normalized epigenetic data, and 388 comprehensive inclusion of novel and complementary epigenetic age measures that were 389 repeatedly collected.

There are also some important limitations. First, was the limitation of small sample size and the lack of a control group. Having epigenetic methylation changes in the control group and a large sample size may have improved statistical power to detect small effects. Likewise, the sample size did not allow a rigorous analysis of individual CpG sites with correction for multiple comparisons. Future, larger studies should replicate the present results and extend them by examining other epigenetic clocks and individual CpG sites with appropriate corrections for multiple testing.

Secondly, epigenetic aging markers were not supplemented with classical blood measurements
 or classical phenotypic markers of aging and thus, it is possible that some unmeasured
 confounders biased our results. However, age acceleration was independent of potential
 confounders including chronological age and sex.

Finally, DNA methylation was measured in blood samples only. As senescence is different in
 every tissue type, blood based DNAm data might not capture the physiologic impact of senolytic
 therapy and future studies in tissue specific analysis might provide more insight.

Future studies can improve on our limitations by including large sample size, additional clinical biomarkers of inflammation and senescence, and incorporate analysis into tissues more associated with senescence related aging phenotypes. We hope this data can be reanalyzed as new senolytic DNA methylation analysis tools become available.

408

410 Materials and methods

411 Study participants and senolytic administration

412 For the evaluation of DQ treatment upon epigenetic age, 19 study participants were accrued 413 from November 2020 to December 2020 at the Institute for Hormonal Balance, Orlando. Table 1 414 shows the demographic and clinical characteristics of these participants. Adults aged 40 and 415 older able to comply with treatment plan and laboratory tests were included. Individuals with 416 neoplastic cancer within 5 years prior to screening, immune disease, viral illness, cardiovascular 417 or cerebrovascular disease, ischemic attack in the last 6 months, hepatitis or HIV, Body mass 418 index higher than 40kg/m2, active infection, or previously used DQ were excluded. Informed 419 consent was obtained from study participants. The FDA registered IRB (Institute for 420 Regenerative and Cellular Medicine) approved this study, which is registered at 421 ClinicalTrials.gov (NCT04946383) and which is an ongoing clinical trial to determine the 422 effectiveness of Quercetin and Dasatinib supplements on the patient's epigenetic aging rate. 423 The treatment comprised 500mg Quercetin and 50mg Dasatinib oral capsules on Monday, 424 Tuesday, and Wednesday (3 days in a row) per month for the duration of 6 months. It is worth 425 mentioning that three subjects stopped the treatment after 3 months due to nausea, prostate 426 cancer diagnosis, and concern about the drug, respectively.

427 For the evaluation of DQF treatment, all the participants from the first study were invited to join 428 and new participants were recruited from June 2022 to July 2022 at the Institute for Hormonal 429 Balance, Orlando. From the previous study, 10 participants joined this study, and 9 participants were newly recruited. The same inclusion and exclusion criteria were followed as in the DQ 430 431 study. In this case, the treatment consisted of the same dosage and timeline as in the DQ 432 treatment but included 500 mg of Fisetin oral capsules on Monday, Tuesday, and Wednesday 433 (3 days in a row) per month for the duration of 6 months. Moreover, 8 participants got a 434 strawberry based Fisetin and 11 got a non-strawberry based Fisetin.

435

436 **DNA methylation assessment**

437 Peripheral whole blood samples were obtained using the lancet and capillary method and 438 immediately mixed with lysis buffer to preserve the cells. DNA extraction was performed, and 439 500 ng of DNA was subjected to bisulfite conversion using the EZ DNA Methylation kit from 440 Zymo Research, following the manufacturer's protocol. The bisulfite-converted DNA samples 441 were then randomly allocated to designated wells on the Infinium HumanMethylationEPIC 442 BeadChip. The samples were amplified, hybridized onto the array, and subsequently stained. 443 After washing steps, the array was imaged using the Illumina iScan SQ instrument to capture 444 raw image intensities, enabling further analysis.

445 *Minfi* R package was used for the pre-processing of DNAm data. We pre-processed all the 446 samples from the different studies together to remove batch effects. In the sample quality 447 control, we removed those samples with aberrant methylation levels and with background signal 448 levels (mean p-value higher than 0.05). We also discarded those probes with background signal 449 following the same threshold. We further normalized the methylation values using the Genome-450 wide Median Normalization (GMQN) and the Beta Mixture Quantile (BMIQ) methods, Finally, we 451 imputed the missing values using the k-nearest neighbors (knn) algorithm. Finally, we used a 452 12-cell immune deconvolution method developed by Zhend et al to estimate cell type 453 proportions. We chose this method because in previous analysis we saw this has R² of 0.96 and 454 above to immune cell subsets measured by RNA-seq and flow cytometry [55].

455

456 Statistical analyses and reproducibility

457 DNA methylation clocks and related measures

458 We used DNAm data to calculate a series of measures broadly known as epigenetic clocks. We 459 computed four clocks designed to predict the chronological age of the donor, Horvath Pan 460 Tissue, Horvath Skin and Blood, and Hannum; two clocks designed to predict mortality, the 461 DNAmPhenoAge and GrimAge clocks; a clock to measure telomere length, DNAmTL [36]; two 462 clock designed to measure mitotic age, total stem cell divisions (tnsc) and intrinsic tissue stem 463 cell division (irS) [56]; a DNAm measure of the rate of deterioration in physiological integrity, the 464 DundedinPACE; and a clock to measure chronological age but not dependent on immune cells, 465 the IntrinClock.

466 To calculate the principal component-based epigenetic clock for the Horvath multi-tissue clock, 467 Hannum clock, DNAmPhenoAge clock, GrimAge clock, and telomere length we used the 468 custom R script available via GitHub (https://github.com/MorganLevineLab/PC-Clocks). Non-469 principal component-based (non-PC) Horvath, Hannum, and DNAmPhenoAge epigenetic 470 metrics were calculated using the methyAge function in the ENMix R package. The pace of 471 aging clock, DunedinPACE, was calculated using the PACEProjector function from the 472 DunedinPACE package available via GitHub (https://github.com/danbelsky/DunedinPACE). The 473 mitotic clocks were calculated using the epiTOC2 function from the meffonym package. Finally, 474 the IntrinClock was calculated as described elsewhere [53].

To calculate the EAA of multiple clocks, we fit a regression model between the chronological age of the individuals and the different epigenetic age measures. We also included the batch PCs as a fixed effect as a way to control for potential batch effects. This methodology of incorporating PCs in EAA calculations was previously described in Joyce et al.

479

480 Differentially methylated loci analysis

The epigenome-wide association study (EWAS) was performed using the *limma* Bioconductor package. We performed a differential mean analysis on different timepoints to see whether the treatment was associated with changes at specific loci. Based on the available covariates, we
adjusted all the regression models by sex, age, batch effect, and three principal components.
We also set as random effect the participant ID. For each timepoint comparison, we fitted
models

487
$$E_j = \alpha_j + \beta_j S + \Sigma \gamma_r C_r + \varepsilon_j$$
(1)

where E_j denotes the methylation level vector across individuals at probe j (j = 1, ... 866836), S is the time point with its associated effect, β_j , C_r is the r adjusting covariate and its effect γ_r , and ϵ_j is the noise that follows the distribution of methylation levels with mean 0. Adjusted P-values were calculated using FDR correction for considering multiple comparisons. The inflation or deflation of P-values across the methylome was assessed with Q-Q plots and lambda values. We selected as significant probes those with FDR lower than 0.05 after correcting for multiple comparisons.

We next used GREAT to understand the functional relevance of the differentially methylated loci (DML) with a nominal p-value lower than $1 \cdot 10^{-4}$. The GREAT software will compare genomic features against the genes of interest in order to run Gene Ontology (GO) analysis. This software looks at the number of DMLs which overlap to the promoter and enhancer regions to run a binomial enrichment analysis of identifying overrepresented/enriched GO terms.

500

501 Author contributions

502 EL performed patient recruitment, clinical management, and sample procurement. NC and VD 503 performed methylation preprocessing, data analysis, and statistical analysis. EV and AT 504 analyzed IntrinClock data. LN and MC provided immune cell subset analysis. TM conducted 505 methylation laboratory analysis. HW, AL, LT, LL, and RS helped with study design, manuscript 506 drafting, and submission.

- 508 Acknowledgements
- 509 We are grateful to all participants and researchers who took part in this study.
- 510
- 511 Conflicts of interest
- 512 NC, VBD, RS, HW, AL, LT, and TLM are employees of TruDiagnostic.
- 513
- 514

515

516 Ethical Statement

517 The study involving human participants was reviewed and approved by the Institute for 518 Regenerative and Cellular Medicine. The participants provided informed consent to participate

- 519 in this study.
- 520
- 521 <u>Funding</u>

522 TruDiagnostic has provided funding for data analysis and IRB funding. The Institute for 523 Hormonal Balance provided all other costs associated with testing and patient recruitment.

524

525 Supplementary Materials

526 Figure S1. Boxplot showing the evolution of epigenetic age acceleration (EAA) first-generation 527 clocks after adjusting by immune cells in the Dasatinib and Quercetin (DQ) study.

528 Table S1. Differentially methylated loci for Dasatinib and Quercetin (DQ) treatment and 529 Dasatinib, Quercetin, and Fisetin (DQF) treatment.

Table S2. Statistical analysis for comparing baseline, 3 month, and 6 month Marioni markersproportions in the Dasatinib and Quercetin Study.

532

533 <u>References</u>

- T. Tchkonia, Y. Zhu, J. Van Deursen, J. Campisi, and J. L. Kirkland, "Cellular senescence
 and the senescent secretory phenotype: therapeutic opportunities," *J Clin Invest*, vol.
 123, no. 3, pp. 966–972, Mar. 2013, doi: 10.1172/JCI64098.
- 537 [2] L. Hayflick, "The limited in vitro lifetime of human diploid cell strains," *Exp Cell Res*, vol.
 538 37, no. 3, pp. 614–636, Mar. 1965, doi: 10.1016/0014-4827(65)90211-9.
- J. Campisi and F. D'Adda Di Fagagna, "Cellular senescence: when bad things happen to
 good cells," *Nature Reviews Molecular Cell Biology 2007 8:9*, vol. 8, no. 9, pp. 729–740,
 Sep. 2007, doi: 10.1038/nrm2233.
- 542[4]C. Kang, "Senolytics and Senostatics: A Two-Pronged Approach to Target Cellular543Senescence for Delaying Aging and Age-Related Diseases.," *Mol Cells*, vol. 42, no. 12,
- 544 pp. 821–827, Dec. 2019, doi: 10.14348/molcells.2019.0298.
- 545[5]V. Gorgoulis *et al.*, "Cellular Senescence: Defining a Path Forward," *Cell*, vol. 179, no. 4.546Cell Press, pp. 813–827, Oct. 31, 2019. doi: 10.1016/j.cell.2019.10.005.

- 547[6]S. He and N. E. Sharpless, "Senescence in Health and Disease," *Cell*, vol. 169, no. 6, pp.5481000–1011, Jun. 2017, doi: 10.1016/j.cell.2017.05.015.
- 549[7]M. Xu *et al.*, "Senolytics improve physical function and increase lifespan in old age," *Nat*550*Med*, vol. 24, no. 8, pp. 1246–1256, Aug. 2018, doi: 10.1038/s41591-018-0092-9.
- 551 [8]M. Xu *et al.*, "Transplanted Senescent Cells Induce an Osteoarthritis-Like Condition in552Mice," J Gerontol A Biol Sci Med Sci, p. glw154, Aug. 2016, doi: 10.1093/gerona/glw154.
- 553 [9] C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, "The Hallmarks
 554 of Aging," *Cell*, vol. 153, no. 6, pp. 1194–1217, Jun. 2013, doi:
 555 10.1016/j.cell.2013.05.039.
- J. Guo *et al.*, "Aging and aging-related diseases: from molecular mechanisms to
 interventions and treatments," *Signal Transduct Target Ther*, vol. 7, no. 1, p. 391, Dec.
 2022, doi: 10.1038/s41392-022-01251-0.
- 559 [11] B. K. Kennedy *et al.*, "Geroscience: Linking Aging to Chronic Disease," *Cell*, vol. 159, no.
 560 4, pp. 709–713, Nov. 2014, doi: 10.1016/j.cell.2014.10.039.
- 561 [12] J. L. Kirkland and T. Tchkonia, "Senolytic drugs: from discovery to translation," *J Intern* 562 *Med*, vol. 288, no. 5, pp. 518–536, Nov. 2020, doi: 10.1111/joim.13141.
- 563 [13] A. Gnoni, I. Marech, N. Silvestris, A. Vacca, and V. Lorusso, "Dasatinib: An Anti-Tumour
 564 Agent via Src Inhibition," *Curr Drug Targets*, vol. 12, no. 4, pp. 563–578, Apr. 2011, doi:
 565 10.2174/138945011794751591.
- 566[14]M. Ichwan *et al.*, "Apple Peel and Flesh Contain Pro-neurogenic Compounds," Stem Cell567Reports, vol. 16, no. 3, pp. 548–565, Mar. 2021, doi: 10.1016/j.stemcr.2021.01.005.
- 568 [15] N. Khan, D. N. Syed, N. Ahmad, and H. Mukhtar, "Fisetin: A Dietary Antioxidant for
 569 Health Promotion," *Antioxid Redox Signal*, vol. 19, no. 2, pp. 151–162, Jul. 2013, doi:
 570 10.1089/ars.2012.4901.
- 571 [16] E. O. Wissler Gerdes, Y. Zhu, T. Tchkonia, and J. L. Kirkland, "Discovery, development,
 572 and future application of senolytics: theories and predictions," *FEBS J*, vol. 287, no. 12,
 573 pp. 2418–2427, Jun. 2020, doi: 10.1111/febs.15264.
- 574 [17] L. J. Hickson *et al.*, "Senolytics decrease senescent cells in humans: Preliminary report
 575 from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease,"
 576 *EBioMedicine*, vol. 47, pp. 446–456, Sep. 2019, doi: 10.1016/j.ebiom.2019.08.069.
- 577 [18] M. T. Islam *et al.*, "Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue
 578 inflammation, and ameliorate metabolic function in old age," *Aging Cell*, vol. 22, no. 2,
 579 Feb. 2023, doi: 10.1111/acel.13767.
- 580 [19] S. Ijima *et al.*, "Fisetin reduces the senescent tubular epithelial cell burden and also
 581 inhibits proliferative fibroblasts in murine lupus nephritis," *Front Immunol*, vol. 13, Nov.
 582 2022, doi: 10.3389/fimmu.2022.960601.
- W. S. Hambright *et al.*, "The Senolytic Drug Fisetin Attenuates Bone Degeneration in the
 Zmpste24-/- Progeria Mouse Model," *J Osteoporos*, vol. 2023, pp. 1–12, Feb. 2023, doi:
 10.1155/2023/5572754.
- 586[21]M. J. Schafer *et al.*, "Cellular senescence mediates fibrotic pulmonary disease," Nat587Commun, vol. 8, no. 1, p. 14532, Feb. 2017, doi: 10.1038/ncomms14532.

- 588 [22] E. J. Novais *et al.*, "Long-term treatment with senolytic drugs Dasatinib and Quercetin
 589 ameliorates age-dependent intervertebral disc degeneration in mice," *Nat Commun*, vol.
 590 12, no. 1, p. 5213, Sep. 2021, doi: 10.1038/s41467-021-25453-2.
- 591 [23] A. D. Ruggiero *et al.*, "Long-term dasatinib plus quercetin effects on aging outcomes and
 592 inflammation in nonhuman primates: implications for senolytic clinical trial design,"
 593 *Geroscience*, Jun. 2023, doi: 10.1007/s11357-023-00830-5.
- [24] N. S. Gasek, G. A. Kuchel, J. L. Kirkland, and M. Xu, "Strategies for targeting senescent cells in human disease," *Nat Aging*, vol. 1, no. 10, pp. 870–879, Oct. 2021, doi: 10.1038/s43587-021-00121-8.
- 597 [25] N. Afroze *et al.*, "Fisetin Deters Cell Proliferation, Induces Apoptosis, Alleviates Oxidative
 598 Stress and Inflammation in Human Cancer Cells, HeLa," *Int J Mol Sci*, vol. 23, no. 3, p.
 599 1707, Feb. 2022, doi: 10.3390/ijms23031707.
- 600 [26] M. J. Yousefzadeh *et al.*, "Fisetin is a senotherapeutic that extends health and lifespan,"
 601 *EBioMedicine*, vol. 36, pp. 18–28, Oct. 2018, doi: 10.1016/j.ebiom.2018.09.015.
- 602 [27] C. G. Bell *et al.*, "DNA methylation aging clocks: challenges and recommendations,"
 603 *Genome Biol*, vol. 20, no. 1, p. 249, Dec. 2019, doi: 10.1186/s13059-019-1824-y.
- T. Bergsma and E. Rogaeva, "DNA Methylation Clocks and Their Predictive Capacity for
 Aging Phenotypes and Healthspan," *Neurosci Insights*, vol. 15, p. 263310552094222,
 Jan. 2020, doi: 10.1177/2633105520942221.
- 607 [29] S. Horvath, "DNA methylation age of human tissues and cell types," *Genome Biol*, vol.
 608 14, no. 10, p. R115, 2013, doi: 10.1186/gb-2013-14-10-r115.
- 609 [30] G. Hannum *et al.*, "Genome-wide Methylation Profiles Reveal Quantitative Views of
 610 Human Aging Rates," *Mol Cell*, vol. 49, no. 2, pp. 359–367, Jan. 2013, doi:
 611 10.1016/j.molcel.2012.10.016.
- 612 [31] M. E. Levine *et al.*, "An epigenetic biomarker of aging for lifespan and healthspan," *Aging*,
 613 vol. 10, no. 4, pp. 573–591, Apr. 2018, doi: 10.18632/aging.101414.
- 614 [32] A. T. Lu *et al.*, "DNA methylation GrimAge strongly predicts lifespan and healthspan,"
 615 *Aging*, vol. 11, no. 2, pp. 303–327, Jan. 2019, doi: 10.18632/aging.101684.
- 616 [33] D. W. Belsky *et al.*, "DunedinPACE, a DNA methylation biomarker of the pace of aging,"
 617 *Elife*, vol. 11, Jan. 2022, doi: 10.7554/eLife.73420.
- 618 [34] T. H. Jonkman *et al.*, "Functional genomics analysis identifies T and NK cell activation as
 619 a driver of epigenetic clock progression," *Genome Biol*, vol. 23, no. 1, p. 24, Dec. 2022,
 620 doi: 10.1186/s13059-021-02585-8.
- [35] S. Victorelli and J. F. Passos, "Telomeres and Cell Senescence Size Matters Not," *EBioMedicine*, vol. 21, pp. 14–20, Jul. 2017, doi: 10.1016/j.ebiom.2017.03.027.
- 623 [36] A. T. Lu *et al.*, "DNA methylation-based estimator of telomere length," *Aging*, vol. 11, no.
 624 16, pp. 5895–5923, Aug. 2019, doi: 10.18632/aging.102173.
- B. J. Zerlanko, L. Bartholin, T. A. Melhuish, and D. Wotton, "Premature Senescence and Increased TGFβ Signaling in the Absence of Tgif1," *PLoS One*, vol. 7, no. 4, p. e35460, Apr. 2012, doi: 10.1371/journal.pone.0035460.

- M. Liesenfeld *et al.*, "SORBS2 and TLR3 induce premature senescence in primary
 human fibroblasts and keratinocytes.," *BMC Cancer*, vol. 13, p. 507, Oct. 2013, doi:
 10.1186/1471-2407-13-507.
- 631 [39] R. Villot *et al.*, "ZNF768 links oncogenic RAS to cellular senescence," *Nat Commun*, vol.
 632 12, no. 1, Dec. 2021, doi: 10.1038/S41467-021-24932-W.
- 633 [40] C. D. Wiley and J. Campisi, "From Ancient Pathways to Aging Cells-Connecting
 634 Metabolism and Cellular Senescence.," *Cell Metab*, vol. 23, no. 6, pp. 1013–1021, Jun.
 635 2016, doi: 10.1016/j.cmet.2016.05.010.
- E.-Y. Shin, N.-K. Soung, M. A. Schwartz, and E.-G. Kim, "Altered endocytosis in cellular senescence.," *Ageing Res Rev*, vol. 68, p. 101332, Jul. 2021, doi:
 10.1016/j.arr.2021.101332.
- 639 [42] O. Moujaber *et al.*, "Cellular senescence is associated with reorganization of the
 640 microtubule cytoskeleton," *Cellular and Molecular Life Sciences*, vol. 76, no. 6, pp. 1169–
 641 1183, Mar. 2019, doi: 10.1007/s00018-018-2999-1.
- 642 [43] D. Muñoz-Espín *et al.*, "Programmed Cell Senescence during Mammalian Embryonic
 643 Development," *Cell*, vol. 155, no. 5, pp. 1104–1118, Nov. 2013, doi:
 644 10.1016/J.CELL.2013.10.019.
- 645 [44] C. Abbadie, O. Pluquet, and A. Pourtier, "Epithelial cell senescence: an adaptive
 646 response to pre-carcinogenic stresses?," *Cellular and Molecular Life Sciences*, vol. 74,
 647 no. 24, pp. 4471–4509, Dec. 2017, doi: 10.1007/s00018-017-2587-9.
- 648 [45] C. A. Valenzuela, R. Quintanilla, R. Moore-Carrasco, and N. E. Brown, "The Potential
 649 Role of Senescence As a Modulator of Platelets and Tumorigenesis.," *Front Oncol*, vol. 7,
 650 p. 188, 2017, doi: 10.3389/fonc.2017.00188.
- [46] V. J. D. Krouwer, L. H. P. Hekking, M. Langelaar-Makkinje, E. Regan-Klapisz, and J.
 Post, "Endothelial cell senescence is associated with disrupted cell-cell junctions and increased monolayer permeability," *Vasc Cell*, vol. 4, no. 1, p. 12, 2012, doi: 10.1186/2045-824X-4-12.
- M. S. Chen, R. T. Lee, and J. C. Garbern, "Senescence mechanisms and targets in the heart.," *Cardiovasc Res*, vol. 118, no. 5, pp. 1173–1187, Mar. 2022, doi: 10.1093/cvr/cvab161.
- 658 [48] D. A. Gadd *et al.*, "Epigenetic scores for the circulating proteome as tools for disease 659 prediction," *Elife*, vol. 11, Jan. 2022, doi: 10.7554/eLife.71802.
- M. E. Levine, A. Higgins-Chen, K. Thrush, C. Minteer, and P. Niimi, "Clock Work:
 Deconstructing the Epigenetic Clock Signals in Aging, Disease, and Reprogramming",
 doi: 10.1101/2022.02.13.480245.
- [50] D. McHugh and J. Gil, "Senescence and aging: Causes, consequences, and therapeutic
 avenues," *Journal of Cell Biology*, vol. 217, no. 1, pp. 65–77, Jan. 2018, doi:
 10.1083/jcb.201708092.
- 666 [51] S. Kabacik *et al.*, "The relationship between epigenetic age and the hallmarks of aging in
 667 human cells," *Nature Aging 2022 2:6*, vol. 2, no. 6, pp. 484–493, May 2022, doi:
 668 10.1038/s43587-022-00220-0.

- R. Waziry *et al.*, "Effect of long-term caloric restriction on DNA methylation measures of
 biological aging in healthy adults from the CALERIE trial," *Nature Aging 2023 3:3*, vol. 3,
 no. 3, pp. 248–257, Feb. 2023, doi: 10.1038/s43587-022-00357-y.
- 672 [53] A. Tomusiak *et al.*, "Development of a novel epigenetic clock resistant to changes in
 673 immune cell composition," *bioRxiv*, p. 2023.03.01.530561, Mar. 2023, doi:
 674 10.1101/2023.03.01.530561.
- E. L. S. Conole *et al.*, "DNA Methylation and Protein Markers of Chronic Inflammation and
 Their Associations With Brain and Cognitive Aging," *Neurology*, vol. 97, no. 23, pp.
 e2340–e2352, Dec. 2021, doi: 10.1212/WNL.00000000012997.
- [55] Q. Luo *et al.*, "A meta-analysis of immune cell fractions at high resolution reveals novel associations with common 2 phenotypes and health outcomes", doi:
 10.1101/2023.03.20.533349.
- 681 [56] B. C. Christensen and K. T. Kelsey, "A new timepiece: An epigenetic mitotic clock,"
 682 *Genome Biol*, vol. 17, no. 1, pp. 1–3, Oct. 2016, doi: 10.1186/S13059-016-1085683 Y/METRICS.
- 684





Time points

Time points

Α







50mg Dasatinib + 500mg Quercetin



N = 19



Baseline blood sample

Jun 2022

50mg Dasatinib + 500mg Quercetin + 500mg Fisetin











